Aims: To evaluate how often patients with moderate-to-severe or severe mitral regurgitation (MR) meet the anatomical criteria for MitraClip implant and to examine the role of transthoracic echocardiography (TTE) for this task.
Methods And Results: From February to June 2015, all patients undergoing a TTE in nine Spanish hospitals were prospectively included. Patients with moderate-to-severe and severe mitral regurgitation were selected for analysis. Anatomical eligibility criteria for MitraClip were defined according to the EVEREST trial. A total of 39 855 consecutive TTE were reviewed, and 1403 patients with moderate-to-severe and severe MR were finally included. Primary MR was found in 779 patients (56%). Only in 74 patients (16%), all anatomical criteria for MitraClip could be assessed by TTE. Of these, 56% of patients had optimal valve morphology. Secondary MR was described in 361 patients (26%), and at least 249 of these (69%) had a high surgical risk. All five criteria for MitraClip were adequately assessed by TTE in 299 patients (83%). Of them, 118 patients (39%) had optimal valve morphology.
Conclusions: A considerable proportion of patients have optimal mitral valve morphology for MitraClip. Moreover, TTE was particularly useful in determining whether or not the anatomical criteria for MitraClip implant were met in the majority of patients with secondary MR but in only a minority of those with primary MR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/echo.13592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
External Validation of COAPT Risk Score in Patients Who Underwent Transcatheter Edge-To-Edge Repair of Severe, Functional Mitral Regurgitation: A Multicenter, Observational Italian-Polish Study.
Am J Cardiol
November 2024
1(st) Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Article Synopsis
- The COAPT Risk Score predicts the likelihood of death or hospitalization for heart failure within two years after undergoing transcatheter edge-to-edge repair for mitral regurgitation using the MitraClip device.
- An international study analyzed 344 patients categorized as COAPT eligible or non-eligible based on COAPT trial criteria, finding higher risk scores associated with increased mortality and hospitalization.
- Overall, the COAPT Score had poor predictive accuracy for both groups, showing better performance in lower-risk patients compared to higher-risk patients, suggesting the Score's effectiveness varies according to patient baseline risk.
Tricuspid Valve Transcatheter Edge-to-Edge Repair (TriClip): Initial Outcomes and Experience in Türkiye.
Turk Kardiyol Dern Ars
September 2024
Department of Cardiology, Bahçeşehir University, Faculty of Health Sciences, İstanbul, Türkiye.
Objective: This study aims to assess the efficacy and safety of tricuspid valve (TV) transcatheter edge-to-edge repair (TEER) procedures using the MitraClip or TriClip device in high-risk patients with severe secondary tricuspid regurgitation (TR) and provide Turkish-specific data on procedural outcomes and clinical follow-up.
Methods: This study enrolled 42 high-risk patients with severe secondary TR who underwent transcatheter edge-to-edge repair using either the MitraClip or TriClip device. Patient selection criteria included severe TR, high surgical risk (EuroScore ≥ 8 and Tricuspid Regurgitation Impact Severity Score (TRI-SCORE) ≥ 6), symptomatic despite medical therapy, and anatomical suitability for TriClip.
Eligibility to COAPT trial in the daily practice: A real-world experience.
Catheter Cardiovasc Interv
August 2024
Department of Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy.
Background: The COAPT Trial was the first ever to demonstrate a survival benefit in treating functional mitral regurgitation (FMR). That was achieved through transcatheter mitral repair in selected patients. The exact proportion of patients fulfilling COAPT selection criteria in the real-world is unknown.
View Article and Find Full Text PDFOutcomes of mitral TEER in non-responders to cardiac resynchronization therapy: A systematic review and meta-analysis.
J Cardiol
November 2024
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Article Synopsis
- Secondary mitral regurgitation (MR) worsens in 10-15% of heart failure patients receiving cardiac resynchronization therapy (CRT), and transcatheter edge-to-edge repair (TEER) with Mitra-Clip shows promise in improving outcomes for those who are CRT non-responders.
- A meta-analysis of 439 patients indicated that Mitra-Clip significantly reduced MR severity and improved symptoms in a majority of CRT non-responders within six months and one year post-procedure.
- The mortality rates for patients after undergoing TEER with Mitra-Clip were similar to those observed in previous studies, with 30-day, 6-month, 1-year, and 2-year mortality rates at
Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design.
Eur J Heart Fail
April 2024
Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Aims: The safety and effectiveness of the MitraClip device to treat functional mitral regurgitation (FMR) has been tested in previous clinical trials yielding somewhat heterogeneous results in heart failure (HF) patients. Over time, the MitraClip device system has been modified and clinical practice evolved to consider also less severely diseased HF patients with FMR for this therapeutic option. The RESHAPE-HF2 trial aims to assess the safety and effectiveness of the MitraClip device system on top of medical therapy considered optimal in the treatment of clinically significant FMR in symptomatic patients with chronic HF.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!